Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease

Clinical and Laboratory Haematology

Volumn 21, Issue 5, 1999, Pages 353-357

  Ratcliffe, M ^a,b   Broadfoot, C ^a   Davidson, M ^a   Kelly, K F ^a   Greaves, M ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

Catheters; Malignancy markers; Prophylaxis; Thrombosis

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; DNA; FIBRINOGEN; IMMUNOGLOBULIN G; LUPUS ANTICOAGULANT; WARFARIN;

ADULT; AGED; ANTIBODY TITER; ANTICOAGULANT THERAPY; ARTICLE; CANCER PATIENT; CENTRAL VENOUS CATHETERIZATION; FEMALE; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC SYSTEM TUMOR; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT MONITORING; PRIORITY JOURNAL; SOLID TUMOR; THROMBOSIS; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

ANTICOAGULANTS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CATHETERIZATION, CENTRAL VENOUS; HUMANS; NEOPLASMS; THROMBOSIS; WARFARIN;

EID: 0033460275     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.1999.00250.x     Document Type: Article

References (22)

1. Bern M.M., Lokich J.J., Wallach S.R. et al. (1990) Very low doses of warfarin can prevent thrombosis in central venous catheters. Annals of Internal Medicine 112, 423-428.
2. Boraks P., Scale J., Price J. et al. (1998) Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies. British Journal of Haematology 101, 483-486.
3. Creagh M.D., Malia R.G., Cooper S.M., Smith A.R., Duncan S.L.B. & Greaves M. (1991) Screening for the lupus anticoagulant and anticardiolipin antibodies in women with fetal loss. Journal of Clinical Pathology 44, 45-47.
4. Eastridge B.J. & Lefor A.T. (1995) Complications of indwelling venous access devices in cancer patients. Journal of Clinical Oncology 13, 233-238.
5. Folkman J., Langer R., Lindhardt R.J., Haudenschild C. & Taylor S. (1983) Angiogenesis inhibition and tumour regression caused by heparin or heparin fragment in the presence of cortisone. Science 221, 719-725.
6. Francis C.W., Felcher A.H., White J., Braaten J.V. & Goss R. (1997) Thrombin activity associated with indwelling central venous catheters. Thrombosis and Haemostasis 77, 48-52.
7. Goad K.E. & Gralnick H.R. (1996) Coagulation disorders in cancer. Haematology and Oncology Clinics of North America 10, 457-484.
8. Green K.B. & Silverstein R.L. (1996) Hypercoagulability in cancer. Haematology and Oncology Clinics of North America 10, 499-529.
9. Green D., Hull R.D., Brant R. & Pineo G.F. (1992) Lower mortality in cancer patients treated with low-molecular weight versus standard heparin. Lancet 339, 1476 (letter).
10. Green D., Maliekel K., Shusko E., Akhtar R. & Soff G.A. (1997) Activated protein C resistance in cancer patients. Haemostasis 27, 112-118.
11. Jude B., Goudemand J., Dolle I. et al. (1988) Lupus anticoagulant. A clinical and laboratory study of 100 cases. Clinical and Laboratory Haematology 10, 41-51.
12. Koster T., Rosendaal F.R., Reitsma P.H., van der Velden P.A., Briet E. & Vandenbroucke J.P. (1994) Factor VII and fibrinogen levels as risk factors for venous thrombosis. A case-control study of plasma levels and DNA polymorphisms - the Leiden Thrombophilia Study (LETS). Thrombosis and Haemostasis 71, 719-722.
13. Koster T., Blann A.D., Briet E., Vandenbroucke J.P. & Rosendaal F.R. (1995) Role of clotting factor VIII in effect of Von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 345, 152-155.
14. Machin S.J., Giddings J.C., Greaves M. et al. (1991) Guidelines on testing for the lupus anticoagulant. Prepared by the Working Party of the BCSH Blood Transfusion Task Force. Journal of Clinical Pathology 44, 885-889.
15. Miller S.P., Sanchez A.J., Stefanski T. & Zuckerman L. (1967) Coagulation disorders in cancer. I. Clinical and laboratory studies. Cancer 20, 1452-1465.
16. Minna J.D. & Bunn P.A., Jr. (1989) Paraneoplastic syndromes. In: DeVita V.T. Jr, Hellman S., Rosenberg S.A., eds. Cancer: Principles and Practice of Oncology, 3rd edn. Philadelphia, PA, Lippincott, pp. 1920-1940.
17. Monreal M., Alastrue A., Rull M. et al. (1996) Upper extremity deep venous thrombosis in cancer patients with venous access devices. Prophylaxis with a low molecular weight heparin (Fragmin). Thrombosis and Haemostasis 75, 251-253.
18. Prandoni P. (1997) Antithrombotic strategies in patients with cancer. Thrombosis and Haemostasis 78, 141-144.
19. Raad I.I., Luna M., Sayed-Ahmed M. et al. ( 1994) The relationship between thrombotic and infectious complications of central venous catheters. Journal of the American Medical Association 271, 1014-1016.
20. Ray S., Stacey R., Irmrie M. & Filshie J. (1996) A review of 560 Hickman catheter insertions. Anaesthesia 51, 981-985.
21. Trousseau A. (1865) Phlegmasia alba dolens. Clinique Medicale de l'Hotel-Dieu de paris. The New Sydenham Society, London 3, 94.
22. Zuckerman E., Toubi E. & Golan T.D. et al. (1995) Increased thromboembolic incidence in anti-cardiolipin positive patients with malignancy. British Journal of Cancer 72, 447-451.